CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 275 enrolled
Drug / intervention
ASP2151drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02209324
NCT02209324Phase 3Completed
CompareCT.gov

Open-label Study of ASP2151 in Herpes Simplex Patients

Maruho Co., Ltd.·interventional·Posted Aug 5, 2014·Updated Sep 27, 2024

In Brief

A Phase 3 clinical trial evaluating ASP2151 for Herpes Simplex. Completed, enrolled 275 participants across 3 sites.

Detailed Summary

A multicenter, open-label study is conducted to evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (recurrent labial/facial herpes and recurrent genital herpes and Kaposi varicelliform).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Simplex
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 5, 2014
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2015
Study CompletionAug 20, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.9 years ago

Interventions

ASP2151drug